Cargando…

Retrospective study shows that early administration of convalescent plasma in hospitalized COVID‐19 patients may have a positive effect on disease progression

Detalles Bibliográficos
Autores principales:	Birschmann, Ingvild, von Bargen, Katharina, Teune, Michelle, Flottmann, Christian, Knüttgen, Franziska, Knabbe, Cornelius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362730/ https://www.ncbi.nlm.nih.gov/pubmed/35957967 http://dx.doi.org/10.1002/hsr2.714

Ejemplares similares

Humoral and cellular immune response levels at a 1-year follow-up after mild COVID-19
por: Flieder, Tobias, et al.
Publicado: (2022)

Evidence of Long-Lasting Humoral and Cellular Immunity against SARS-CoV-2 Even in Elderly COVID-19 Convalescents Showing a Mild to Moderate Disease Progression
por: Fischer, Bastian, et al.
Publicado: (2021)

Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19
por: Flieder, Tobias, et al.
Publicado: (2021)

UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays
por: Kuhn, Joachim, et al.
Publicado: (2015)

Strain-dependent interactions of Streptococcus gallolyticus subsp. gallolyticus with human blood cells
por: Grimm, Imke, et al.
Publicado: (2017)

Changes in the Proteome of Platelets from Patients with Critical Progression of COVID-19
por: Wolny, Monika, et al.
Publicado: (2023)

Convalescent plasma trial shows no benefit
por: Brown, Matthew
Publicado: (2020)

The Human Myofibroblast Marker Xylosyltransferase-I: A New Indicator for Macrophage Polarization
por: Ly, Thanh-Diep, et al.
Publicado: (2022)

Synergistic effects of levosimendan and convalescence plasma as bailout strategy in acute cardiogenic shock in COVID-19: A case report
por: Fox, Henrik, et al.
Publicado: (2022)

The Sysmex CS-5100 coagulation analyzer offers comparable analytical performance and excellent throughput capabilities
por: Flieder, T., et al.
Publicado: (2016)

Convalescent plasma for administration of passive antibodies against viral agents
por: Di Minno, Giovanni, et al.
Publicado: (2020)

Convalescent plasma treatment of critically ill intensive care COVID‐19 patients
por: Lindemann, Monika, et al.
Publicado: (2021)

Risk factors for COVID-19 mortality: The effect of convalescent plasma administration
por: Salazar, Martín R., et al.
Publicado: (2021)

Management of COVID patients with convalescent plasma: Do we have the final word?
por: Menichetti, Francesco, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
por: Serpa, Priscila B. S., et al.
Publicado: (2018)

Convalescent plasma may be a possible treatment for COVID-19: A systematic review
por: Wang, Ying, et al.
Publicado: (2021)

Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19
por: Biernat, Monika Maria, et al.
Publicado: (2021)

Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19
por: Kocayiğit, Havva, et al.
Publicado: (2021)

How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?
por: Bloch, Evan M., et al.
Publicado: (2022)

Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020)

The resurgence of convalescent plasma therapy
por: The Lancet Haematology
Publicado: (2020)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

Identification of the Coding-Complete Genome Sequence of a Novel Cytorhabdovirus in Tilia cordata Showing Extensive Leaf Chloroses
por: Köpke, Kira, et al.
Publicado: (2023)

Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters
por: Wouters, Elise, et al.
Publicado: (2023)

Convalescent plasma to treat COVID-19
por: Bloch, Evan M.
Publicado: (2020)

Convalescent plasma for patients with COVID-19
por: Zeng, Furong, et al.
Publicado: (2020)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

Serosurveys and convalescent plasma in COVID-19
por: Pérez-Cameo, Cristina, et al.
Publicado: (2020)

COVID-19 convalescent plasma transfusion
por: Langhi, Dante Mário, et al.
Publicado: (2020)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma: Alternative or promising therapy?
por: Mina, Fahmida Begum, et al.
Publicado: (2021)

Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement
por: Fleming, Andrew B., et al.
Publicado: (2020)

First Characterization of Human Dermal Fibroblasts Showing a Decreased Xylosyltransferase-I Expression Induced by the CRISPR/Cas9 System
por: Fischer, Bastian, et al.
Publicado: (2022)

Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019
por: Bainbridge, Emma D, et al.
Publicado: (2021)

Convalescent Plasma Therapy for Coronavirus Disease 2019
por: Choi, Jun Yong
Publicado: (2020)

The true historical origin of convalescent plasma therapy
por: Marson, Piero, et al.
Publicado: (2020)

Efficacy of convalescent plasma for the treatment of severe influenza
por: Xu, Zhiheng, et al.
Publicado: (2020)

Convalescent plasma therapy in patients with COVID-19
por: Altuntas, Fevzi, et al.
Publicado: (2021)

Convalescent plasma therapy in patients with COVID-19
por: Altuntas, Fevzi, et al.
Publicado: (2021)

Donating convalescent plasma for COVID-19 patients
por: Black, Emily
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b55r661tphnbtsjgorq4vrmrso